Last Updated: May 2, 2026

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Dextrose 5%, Sodium Chloride 0.2% And Potassium Chloride 0.15% In Plastic Container, and what generic alternatives are available?

Dextrose 5%, Sodium Chloride 0.2% And Potassium Chloride 0.15% In Plastic Container is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER is dextrose; potassium chloride; sodium chloride. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dextrose; potassium chloride; sodium chloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER?
  • What are the global sales for DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER?
  • What is Average Wholesale Price for DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER?
Summary for DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

US Patents and Regulatory Information for DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
B Braun DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER dextrose; potassium chloride; sodium chloride INJECTABLE;INJECTION 018268-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for Dextrose 5%, Sodium Chloride 0.2%, and Potassium Chloride 0.15% in Plastic Containers

Last updated: February 24, 2026

What is the current market size and growth rate?

The global infusion solutions market, which includes dextrose, sodium chloride, and potassium chloride in plastic containers, was valued at approximately USD 8.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6% through 2028, driven by increasing hospitalizations, outpatient procedures, and bolstered focus on infection control due to the COVID-19 pandemic.

Specifically, the segment comprising dextrose 5%, sodium chloride 0.2%, and potassium chloride 0.15% in plastic containers targets hospitals, clinics, and home-care settings. This segment's direct market size is estimated at USD 1.2 billion in 2022, representing roughly 14% of the overall infusion solutions market, with a projected CAGR of roughly 5.8%.

How do regulatory policies influence market trends?

Regulatory frameworks significantly impact market growth. The U.S. Food and Drug Administration (FDA) requires strict adherence to Good Manufacturing Practices (GMP) and compliance with USP (United States Pharmacopeia) standards for sterility and concentration accuracy.

European Medicines Agency (EMA) and other regulatory bodies enforce similar standards. Countries with more stringent regulations tend to experience slower market penetration but higher product safety standards.

In addition, recent rulings against single-use plastics in certain regions push manufacturers toward environmentally friendly containers, affecting market supply and production costs.

What are key drivers and restraints?

Drivers:

  • Rising prevalence of chronic diseases requiring intravenous therapy, such as diabetes and cancer.
  • Growth in surgical procedures, increasing demand for infusion fluids.
  • Expansion of outpatient care services and home infusion therapy.

Restraints:

  • High cost of raw materials, including bulk chemicals and plastics.
  • Stringent regulatory approvals delaying product launches.
  • Environmental concerns over plastic waste, leading to potential bans or increased costs for sustainable packaging.

What are the competitive landscape and key players?

Major global manufacturers include Baxter International, B. Braun Melsungen AG, Fresenius Kabi, Hospira (a Pfizer business), and Terumo Corporation. Competition revolves around product safety, container integrity, and price.

Product differentiation involves:

  • Container material quality, such as polyethylene or polypropylene.
  • Compatibility with infusion devices.
  • Sterility assurance.
  • Pricing strategies aligned with hospitals’ procurement policies.

Private-label arrangements and regional manufacturer entry also influence market competitiveness.

How does pricing evolve?

Pricing for dextrose and electrolyte solutions in plastic containers varies by region, healthcare setting, and volume. Bulk procurement discounts are common in hospital contracts. Estimated prices per 100 mL in North America range from USD 0.50 to USD 1.50, depending on the formulation and supplier volume.

Cost pressures are heightened by raw material volatility, especially plastics and chemical constituents. Increased regulatory compliance and sustainability initiatives may further elevate production costs.

What is the financial outlook?

The segment's revenue is projected to grow from USD 1.2 billion in 2022 to approximately USD 1.7 billion by 2028, translating to an overall CAGR of 5.8%. The largest share is attributable to North America, representing about 45% of sales, driven by high hospital utilization and advanced healthcare infrastructure.

Emerging markets, including China and India, are expanding rapidly, with CAGR estimates around 8%. These markets benefit from increasing healthcare access and investments but face challenges in regulatory consistency.

How do substitution and technological innovation influence the market?

Substitutes such as pre-filled syringes, multi-dose vials, and alternative fluid compositions impact demand.

Innovations focus on:

  • Development of plastic containers with enhanced sterility and reduced plastic waste.
  • Integration of smart infusion systems.

Market leaders invest in R&D to improve container durability, reduce material costs, and meet regulatory and environmental standards.

Key Takeaways

  • The global infusion solutions market, including dextrose, sodium chloride, and potassium chloride in plastic containers, is growing due to rising medical needs and procedure volumes.
  • Regulations heavily influence market entry, product design, and cost.
  • Competitive advantage hinges on container safety, compliance, and cost efficiency.
  • Price points vary regionally but generally range from USD 0.50 to USD 1.50 per 100 mL.
  • Market revenue is expected to grow at approximately 5.8% CAGR through 2028, with North America leading but emerging markets catching up rapidly.
  • Innovation and environmental compliance shape future product development.

FAQs

Q1: What factors are driving the demand for these infusion solutions?
Rise in chronic disease management, surgical procedures, outpatient therapy, and home healthcare.

Q2: How do environmental policies impact manufacturing?
Restrictive plastic use policies increase costs for eco-friendly containers and innovation investments.

Q3: Which regions are expected to experience the fastest market growth?
Emerging markets, notably China and India, with CAGR estimates around 8%.

Q4: How do price fluctuations affect market competitiveness?
Raw material cost volatility influences pricing strategies and profit margins.

Q5: What innovations are likely to shape the future of infusion container solutions?
Development of sustainable plastics, smarter infusion systems, and improved container safety features.


References

  1. MarketsandMarkets. (2023). Infusion Therapy Devices & Solutions Market by Product. [Data File].
  2. Statista. (2022). Global infusion therapy market size.
  3. U.S. Food and Drug Administration. (2023). Good Manufacturing Practices (GMP) for sterile drug products.
  4. European Medicines Agency. (2023). Regulations on medical device manufacturing standards.
  5. Grand View Research. (2022). Medical Plastic Packaging Market Size & Share.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.